Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-10-22

AUTHORS

Asim Amin, Elizabeth R Plimack, Marc S Ernstoff, Lionel D Lewis, Todd M Bauer, David F McDermott, Michael Carducci, Christian Kollmannsberger, Brian I Rini, Daniel Y C Heng, Jennifer Knox, Martin H Voss, Jennifer Spratlin, Elmer Berghorn, Lingfeng Yang, Hans J Hammers

ABSTRACT

BackgroundCombination treatment with immune checkpoint inhibitors and antiangiogenic drugs has shown encouraging preliminary antitumor activity across various tumor types including advanced or metastatic renal cell carcinoma (aRCC). The open-label, parallel-cohort, dose-escalation, phase I CheckMate 016 study evaluated the efficacy and safety of nivolumab in combination with antiangiogenic tyrosine kinase inhibitors or ipilimumab. Long-term outcomes from this study for the combination of nivolumab plus sunitinib or pazopanib in aRCC are presented.MethodsPatients with aRCC received nivolumab plus either sunitinib (50 mg/day, 4 weeks on/2 weeks off; N + S) or pazopanib (800 mg/day; N + P) until progression/unacceptable toxicity. The nivolumab starting dose was 2 mg/kg every 3 weeks, with planned escalation to 5 mg/kg every 3 weeks. Primary endpoints were safety and tolerability; antitumor activity was a secondary endpoint.ResultsArm N + S enrolled 33 patients, 19 of whom were treatment-naïve; this arm advanced to the expansion phase. Median follow-up was 50.0 months. Patients experienced high frequencies of adverse events (AEs) including treatment-related AEs (100%), grade 3/4 treatment-related AEs (82%), and treatment-related AEs leading to discontinuation (39%). Investigator-assessed objective response rate (ORR) was 55% (18/33) and median progression-free survival (PFS) was 12.7 months. Median overall survival (OS) was not reached.Arm N + P enrolled 20 patients, all had ≥1 prior systemic therapy; this arm was closed due to dose-limiting toxicities and did not proceed to expansion. Median follow-up was 27.1 months. Patients treated with N + P experienced high frequencies of AEs including treatment-related AEs (100%), grade 3/4 treatment-related AEs (70%), and treatment-related AEs leading to discontinuation (25%). Investigator-assessed ORR was 45% (9/20) and median PFS was 7.2 months. Median OS was 27.9 months.ConclusionsThe addition of standard doses of sunitinib or pazopanib to nivolumab resulted in a high incidence of high-grade toxicities limiting future development of either combination regimen. While there was no adverse impact on response and the OS outcome was notable, the findings suggest that the success of combination regimens based on immune checkpoint inhibitors and antiangiogenic drugs may be dependent on careful selection of the antiangiogenic component and dose.Trial registrationClinicaltrials.gov identifier: NCT01472081. Registered 16 November 2011. More... »

PAGES

109

Journal

TITLE

Journal for ImmunoTherapy of Cancer

ISSUE

1

VOLUME

6

Author Affiliations

  • Immunotherapy program, Levine Cancer Institute, Carolinas HealthCare System, 1024 Morehead Medical Drive, 28204, Charlotte, NC, USA
  • Division of Genitourinary Medical Oncology, Department of Hematology/Oncology, Fox Chase Cancer Center, 19111, Philadelphia, PA, USA
  • Division of Oncology, Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, 14203, Buffalo, NY, USA
  • Department of Medicine at The Geisel School of Medicine and The Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, 03756, Lebanon, NH, USA
  • Sarah Cannon Research Institute/Tennessee Oncology, PLLC, 37203, Nashville, TN, USA
  • Department of Medicine, Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, 02215, Boston, MA, USA
  • Department of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, 21287, Baltimore, MD, USA
  • Division of Medical Oncology, British Columbia Cancer Agency, V5Z 4E6, Vancouver, BC, Canada
  • Lerner College of Medicine, Department of Hematology and Oncology, Cleveland Clinic Taussig Cancer Institute, 44195, Cleveland, OH, USA
  • Department of Oncology, Tom Baker Cancer Center, University of Calgary, T2N 4N2, Calgary, AB, Canada
  • Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre, M5G 1Z5, Toronto, ON, Canada
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, 10065, New York, NY, USA
  • Department of Oncology, Cross Cancer Institute, University of Alberta, T6G 1Z2, Edmonton, AB, Canada
  • Oncology - Global Clinical Research, Bristol-Myers Squibb, 08541, Princeton, NJ, USA
  • Department of Internal Medicine, UT Southwestern – Kidney Cancer Program, 75390, Dallas, TX, USA
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1186/s40425-018-0420-0

    DOI

    http://dx.doi.org/10.1186/s40425-018-0420-0

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1107776066

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/30348216


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Clinical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Adult", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antineoplastic Combined Chemotherapy Protocols", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Carcinoma, Renal Cell", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Female", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Indazoles", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Kidney Neoplasms", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Male", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Middle Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Nivolumab", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Pyrimidines", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Sulfonamides", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Sunitinib", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Immunotherapy program, Levine Cancer Institute, Carolinas HealthCare System, 1024 Morehead Medical Drive, 28204, Charlotte, NC, USA", 
              "id": "http://www.grid.ac/institutes/grid.468189.a", 
              "name": [
                "Immunotherapy program, Levine Cancer Institute, Carolinas HealthCare System, 1024 Morehead Medical Drive, 28204, Charlotte, NC, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Amin", 
            "givenName": "Asim", 
            "id": "sg:person.0616232204.47", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0616232204.47"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Division of Genitourinary Medical Oncology, Department of Hematology/Oncology, Fox Chase Cancer Center, 19111, Philadelphia, PA, USA", 
              "id": "http://www.grid.ac/institutes/grid.249335.a", 
              "name": [
                "Division of Genitourinary Medical Oncology, Department of Hematology/Oncology, Fox Chase Cancer Center, 19111, Philadelphia, PA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Plimack", 
            "givenName": "Elizabeth R", 
            "id": "sg:person.0726044621.91", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726044621.91"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Division of Oncology, Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, 14203, Buffalo, NY, USA", 
              "id": "http://www.grid.ac/institutes/grid.240614.5", 
              "name": [
                "Division of Oncology, Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, 14203, Buffalo, NY, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Ernstoff", 
            "givenName": "Marc S", 
            "id": "sg:person.01115160302.45", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01115160302.45"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Medicine at The Geisel School of Medicine and The Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, 03756, Lebanon, NH, USA", 
              "id": "http://www.grid.ac/institutes/grid.413480.a", 
              "name": [
                "Department of Medicine at The Geisel School of Medicine and The Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, 03756, Lebanon, NH, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Lewis", 
            "givenName": "Lionel D", 
            "id": "sg:person.014017277612.37", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014017277612.37"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Sarah Cannon Research Institute/Tennessee Oncology, PLLC, 37203, Nashville, TN, USA", 
              "id": "http://www.grid.ac/institutes/grid.419513.b", 
              "name": [
                "Sarah Cannon Research Institute/Tennessee Oncology, PLLC, 37203, Nashville, TN, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Bauer", 
            "givenName": "Todd M", 
            "id": "sg:person.01343430002.75", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01343430002.75"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Medicine, Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, 02215, Boston, MA, USA", 
              "id": "http://www.grid.ac/institutes/grid.239395.7", 
              "name": [
                "Department of Medicine, Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, 02215, Boston, MA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "McDermott", 
            "givenName": "David F", 
            "id": "sg:person.0656541200.82", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0656541200.82"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, 21287, Baltimore, MD, USA", 
              "id": "http://www.grid.ac/institutes/grid.280502.d", 
              "name": [
                "Department of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, 21287, Baltimore, MD, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Carducci", 
            "givenName": "Michael", 
            "id": "sg:person.01266317743.88", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01266317743.88"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Division of Medical Oncology, British Columbia Cancer Agency, V5Z 4E6, Vancouver, BC, Canada", 
              "id": "http://www.grid.ac/institutes/grid.248762.d", 
              "name": [
                "Division of Medical Oncology, British Columbia Cancer Agency, V5Z 4E6, Vancouver, BC, Canada"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Kollmannsberger", 
            "givenName": "Christian", 
            "id": "sg:person.0660645031.33", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0660645031.33"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Lerner College of Medicine, Department of Hematology and Oncology, Cleveland Clinic Taussig Cancer Institute, 44195, Cleveland, OH, USA", 
              "id": "http://www.grid.ac/institutes/grid.254293.b", 
              "name": [
                "Lerner College of Medicine, Department of Hematology and Oncology, Cleveland Clinic Taussig Cancer Institute, 44195, Cleveland, OH, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Rini", 
            "givenName": "Brian I", 
            "id": "sg:person.01113325143.17", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01113325143.17"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Oncology, Tom Baker Cancer Center, University of Calgary, T2N 4N2, Calgary, AB, Canada", 
              "id": "http://www.grid.ac/institutes/grid.22072.35", 
              "name": [
                "Department of Oncology, Tom Baker Cancer Center, University of Calgary, T2N 4N2, Calgary, AB, Canada"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Heng", 
            "givenName": "Daniel Y C", 
            "id": "sg:person.010437732204.73", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010437732204.73"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre, M5G 1Z5, Toronto, ON, Canada", 
              "id": "http://www.grid.ac/institutes/grid.415224.4", 
              "name": [
                "Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre, M5G 1Z5, Toronto, ON, Canada"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Knox", 
            "givenName": "Jennifer", 
            "id": "sg:person.01270061622.88", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01270061622.88"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Medicine, Memorial Sloan Kettering Cancer Center, 10065, New York, NY, USA", 
              "id": "http://www.grid.ac/institutes/grid.51462.34", 
              "name": [
                "Department of Medicine, Memorial Sloan Kettering Cancer Center, 10065, New York, NY, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Voss", 
            "givenName": "Martin H", 
            "id": "sg:person.0577111044.36", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0577111044.36"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Oncology, Cross Cancer Institute, University of Alberta, T6G 1Z2, Edmonton, AB, Canada", 
              "id": "http://www.grid.ac/institutes/grid.17089.37", 
              "name": [
                "Department of Oncology, Cross Cancer Institute, University of Alberta, T6G 1Z2, Edmonton, AB, Canada"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Spratlin", 
            "givenName": "Jennifer", 
            "id": "sg:person.01275717732.80", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01275717732.80"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Oncology - Global Clinical Research, Bristol-Myers Squibb, 08541, Princeton, NJ, USA", 
              "id": "http://www.grid.ac/institutes/grid.419971.3", 
              "name": [
                "Oncology - Global Clinical Research, Bristol-Myers Squibb, 08541, Princeton, NJ, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Berghorn", 
            "givenName": "Elmer", 
            "id": "sg:person.01255266321.73", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01255266321.73"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Oncology - Global Clinical Research, Bristol-Myers Squibb, 08541, Princeton, NJ, USA", 
              "id": "http://www.grid.ac/institutes/grid.419971.3", 
              "name": [
                "Oncology - Global Clinical Research, Bristol-Myers Squibb, 08541, Princeton, NJ, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Yang", 
            "givenName": "Lingfeng", 
            "id": "sg:person.016162310137.44", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016162310137.44"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Internal Medicine, UT Southwestern \u2013 Kidney Cancer Program, 75390, Dallas, TX, USA", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Department of Internal Medicine, UT Southwestern \u2013 Kidney Cancer Program, 75390, Dallas, TX, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Hammers", 
            "givenName": "Hans J", 
            "id": "sg:person.01220204543.52", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01220204543.52"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1186/s40425-017-0310-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1100433878", 
              "https://doi.org/10.1186/s40425-017-0310-x"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/bjc.2015.196", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1003895805", 
              "https://doi.org/10.1038/bjc.2015.196"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2018-10-22", 
        "datePublishedReg": "2018-10-22", 
        "description": "BackgroundCombination treatment with immune checkpoint inhibitors and antiangiogenic drugs has shown encouraging preliminary antitumor activity across various tumor types including advanced or metastatic renal cell carcinoma (aRCC). The open-label, parallel-cohort, dose-escalation, phase I CheckMate 016 study evaluated the efficacy and safety of nivolumab in combination with antiangiogenic tyrosine kinase inhibitors or ipilimumab. Long-term outcomes from this study for the combination of nivolumab plus sunitinib or pazopanib in aRCC are presented.MethodsPatients with aRCC received nivolumab plus either sunitinib (50\u00a0mg/day, 4\u00a0weeks on/2\u00a0weeks off; N\u2009+\u2009S) or pazopanib (800\u00a0mg/day; N\u2009+\u2009P) until progression/unacceptable toxicity. The nivolumab starting dose was 2\u00a0mg/kg every 3\u00a0weeks, with planned escalation to 5\u00a0mg/kg every 3\u00a0weeks. Primary endpoints were safety and tolerability; antitumor activity was a secondary endpoint.ResultsArm N\u2009+\u2009S enrolled 33 patients, 19 of whom were treatment-na\u00efve; this arm advanced to the expansion phase. Median follow-up was 50.0\u00a0months. Patients experienced high frequencies of adverse events (AEs) including treatment-related AEs (100%), grade 3/4 treatment-related AEs (82%), and treatment-related AEs leading to discontinuation (39%). Investigator-assessed objective response rate (ORR) was 55% (18/33) and median progression-free survival (PFS) was 12.7\u00a0months. Median overall survival (OS) was not reached.Arm N\u2009+\u2009P enrolled 20 patients, all had \u22651 prior systemic therapy; this arm was closed due to dose-limiting toxicities and did not proceed to expansion. Median follow-up was 27.1\u00a0months. Patients treated with N\u2009+\u2009P experienced high frequencies of AEs including treatment-related AEs (100%), grade 3/4 treatment-related AEs (70%), and treatment-related AEs leading to discontinuation (25%). Investigator-assessed ORR was 45% (9/20) and median PFS was 7.2\u00a0months. Median OS was 27.9\u00a0months.ConclusionsThe addition of standard doses of sunitinib or pazopanib to nivolumab resulted in a high incidence of high-grade toxicities limiting future development of either combination regimen. While there was no adverse impact on response and the OS outcome was notable, the findings suggest that the success of combination regimens based on immune checkpoint inhibitors and antiangiogenic drugs may be dependent on careful selection of the antiangiogenic component and dose.Trial registrationClinicaltrials.gov identifier: NCT01472081. Registered 16 November 2011.", 
        "genre": "article", 
        "id": "sg:pub.10.1186/s40425-018-0420-0", 
        "isAccessibleForFree": true, 
        "isFundedItemOf": [
          {
            "id": "sg:grant.2438793", 
            "type": "MonetaryGrant"
          }
        ], 
        "isPartOf": [
          {
            "id": "sg:journal.1049249", 
            "issn": [
              "2051-1426"
            ], 
            "name": "Journal for ImmunoTherapy of Cancer", 
            "publisher": "BMJ", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "1", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "6"
          }
        ], 
        "keywords": [
          "treatment-related adverse events", 
          "objective response rate", 
          "progression-free survival", 
          "grade 3/4 treatment-related adverse events", 
          "investigator-assessed objective response rate", 
          "median progression-free survival", 
          "metastatic renal cell carcinoma", 
          "immune checkpoint inhibitors", 
          "median overall survival", 
          "adverse events", 
          "renal cell carcinoma", 
          "overall survival", 
          "checkpoint inhibitors", 
          "cell carcinoma", 
          "antiangiogenic drugs", 
          "progression/unacceptable toxicity", 
          "antiangiogenic tyrosine kinase inhibitors", 
          "safety of nivolumab", 
          "combination of nivolumab", 
          "efficacy of nivolumab", 
          "antitumor activity", 
          "high-grade toxicity", 
          "preliminary antitumor activity", 
          "long-term outcomes", 
          "tyrosine kinase inhibitors", 
          "starting dose", 
          "primary endpoint", 
          "secondary endpoints", 
          "treatment-na\u00efve", 
          "unacceptable toxicity", 
          "systemic therapy", 
          "combination regimen", 
          "standard doses", 
          "combination regimens", 
          "OS outcomes", 
          "nivolumab", 
          "high incidence", 
          "pazopanib", 
          "response rate", 
          "tumor types", 
          "sunitinib", 
          "patients", 
          "kinase inhibitors", 
          "months", 
          "antiangiogenic component", 
          "discontinuation", 
          "carcinoma", 
          "high frequency", 
          "dose", 
          "inhibitors", 
          "endpoint", 
          "weeks", 
          "drugs", 
          "efficacy", 
          "toxicity", 
          "survival", 
          "outcomes", 
          "ConclusionsThe addition", 
          "safety", 
          "ipilimumab", 
          "MethodsPatients", 
          "tolerability", 
          "regimen", 
          "regimens", 
          "arm", 
          "therapy", 
          "incidence", 
          "doses", 
          "study", 
          "careful selection", 
          "treatment", 
          "activity", 
          "escalation", 
          "combination", 
          "ARCC", 
          "adverse impact", 
          "findings", 
          "arm N", 
          "response", 
          "frequency", 
          "rate", 
          "events", 
          "future development", 
          "addition", 
          "development", 
          "types", 
          "success", 
          "impact", 
          "expansion phase", 
          "identifiers", 
          "components", 
          "selection", 
          "expansion", 
          "phase"
        ], 
        "name": "Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study", 
        "pagination": "109", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1107776066"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1186/s40425-018-0420-0"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "30348216"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1186/s40425-018-0420-0", 
          "https://app.dimensions.ai/details/publication/pub.1107776066"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-09-02T16:02", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_760.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1186/s40425-018-0420-0"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s40425-018-0420-0'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s40425-018-0420-0'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s40425-018-0420-0'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s40425-018-0420-0'


     

    This table displays all metadata directly associated to this object as RDF triples.

    367 TRIPLES      21 PREDICATES      135 URIs      125 LITERALS      21 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1186/s40425-018-0420-0 schema:about N1efb180265214dfa89c8b4393ef7fbe4
    2 N2712b57e3c1e4a1181251c25c7356557
    3 N292e5407421b494192f82997c12bff04
    4 N29faa800a443484e83f55169e5d071d4
    5 N3bbe0469ea444b2fb42b7d52df88b09a
    6 N41e7fe3450854a499af185bbff107c95
    7 N75070f88dd514ddba8f724ab961bab20
    8 N7fe02277ec5d40df97bb03e754da565a
    9 N979458981edb4e52bd347018f48dd9ee
    10 N992be4c452224b079854537071f3825c
    11 N99ce20905a804798b6341f3d65abdb1f
    12 Na092b92f231d48f0908612839645f340
    13 Nb4e8af68b6db4d189f943442cfc6c5b7
    14 Nfee72279967248199482ed3e0aa6a65d
    15 anzsrc-for:11
    16 anzsrc-for:1103
    17 schema:author N09679885948b4bd79d7b65370b9ba11e
    18 schema:citation sg:pub.10.1038/bjc.2015.196
    19 sg:pub.10.1186/s40425-017-0310-x
    20 schema:datePublished 2018-10-22
    21 schema:datePublishedReg 2018-10-22
    22 schema:description BackgroundCombination treatment with immune checkpoint inhibitors and antiangiogenic drugs has shown encouraging preliminary antitumor activity across various tumor types including advanced or metastatic renal cell carcinoma (aRCC). The open-label, parallel-cohort, dose-escalation, phase I CheckMate 016 study evaluated the efficacy and safety of nivolumab in combination with antiangiogenic tyrosine kinase inhibitors or ipilimumab. Long-term outcomes from this study for the combination of nivolumab plus sunitinib or pazopanib in aRCC are presented.MethodsPatients with aRCC received nivolumab plus either sunitinib (50 mg/day, 4 weeks on/2 weeks off; N + S) or pazopanib (800 mg/day; N + P) until progression/unacceptable toxicity. The nivolumab starting dose was 2 mg/kg every 3 weeks, with planned escalation to 5 mg/kg every 3 weeks. Primary endpoints were safety and tolerability; antitumor activity was a secondary endpoint.ResultsArm N + S enrolled 33 patients, 19 of whom were treatment-naïve; this arm advanced to the expansion phase. Median follow-up was 50.0 months. Patients experienced high frequencies of adverse events (AEs) including treatment-related AEs (100%), grade 3/4 treatment-related AEs (82%), and treatment-related AEs leading to discontinuation (39%). Investigator-assessed objective response rate (ORR) was 55% (18/33) and median progression-free survival (PFS) was 12.7 months. Median overall survival (OS) was not reached.Arm N + P enrolled 20 patients, all had ≥1 prior systemic therapy; this arm was closed due to dose-limiting toxicities and did not proceed to expansion. Median follow-up was 27.1 months. Patients treated with N + P experienced high frequencies of AEs including treatment-related AEs (100%), grade 3/4 treatment-related AEs (70%), and treatment-related AEs leading to discontinuation (25%). Investigator-assessed ORR was 45% (9/20) and median PFS was 7.2 months. Median OS was 27.9 months.ConclusionsThe addition of standard doses of sunitinib or pazopanib to nivolumab resulted in a high incidence of high-grade toxicities limiting future development of either combination regimen. While there was no adverse impact on response and the OS outcome was notable, the findings suggest that the success of combination regimens based on immune checkpoint inhibitors and antiangiogenic drugs may be dependent on careful selection of the antiangiogenic component and dose.Trial registrationClinicaltrials.gov identifier: NCT01472081. Registered 16 November 2011.
    23 schema:genre article
    24 schema:isAccessibleForFree true
    25 schema:isPartOf N979187772f4a4f2bac77ab78310fc222
    26 Ne7a7dd34fcd24991806fd7d71b599720
    27 sg:journal.1049249
    28 schema:keywords ARCC
    29 ConclusionsThe addition
    30 MethodsPatients
    31 OS outcomes
    32 activity
    33 addition
    34 adverse events
    35 adverse impact
    36 antiangiogenic component
    37 antiangiogenic drugs
    38 antiangiogenic tyrosine kinase inhibitors
    39 antitumor activity
    40 arm
    41 arm N
    42 carcinoma
    43 careful selection
    44 cell carcinoma
    45 checkpoint inhibitors
    46 combination
    47 combination of nivolumab
    48 combination regimen
    49 combination regimens
    50 components
    51 development
    52 discontinuation
    53 dose
    54 doses
    55 drugs
    56 efficacy
    57 efficacy of nivolumab
    58 endpoint
    59 escalation
    60 events
    61 expansion
    62 expansion phase
    63 findings
    64 frequency
    65 future development
    66 grade 3/4 treatment-related adverse events
    67 high frequency
    68 high incidence
    69 high-grade toxicity
    70 identifiers
    71 immune checkpoint inhibitors
    72 impact
    73 incidence
    74 inhibitors
    75 investigator-assessed objective response rate
    76 ipilimumab
    77 kinase inhibitors
    78 long-term outcomes
    79 median overall survival
    80 median progression-free survival
    81 metastatic renal cell carcinoma
    82 months
    83 nivolumab
    84 objective response rate
    85 outcomes
    86 overall survival
    87 patients
    88 pazopanib
    89 phase
    90 preliminary antitumor activity
    91 primary endpoint
    92 progression-free survival
    93 progression/unacceptable toxicity
    94 rate
    95 regimen
    96 regimens
    97 renal cell carcinoma
    98 response
    99 response rate
    100 safety
    101 safety of nivolumab
    102 secondary endpoints
    103 selection
    104 standard doses
    105 starting dose
    106 study
    107 success
    108 sunitinib
    109 survival
    110 systemic therapy
    111 therapy
    112 tolerability
    113 toxicity
    114 treatment
    115 treatment-naïve
    116 treatment-related adverse events
    117 tumor types
    118 types
    119 tyrosine kinase inhibitors
    120 unacceptable toxicity
    121 weeks
    122 schema:name Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
    123 schema:pagination 109
    124 schema:productId N46c8710e115a4ea0b719e39f1b2968f8
    125 Nae0046fc25e54bcfbc97451bc74995a7
    126 Nee59aff7666447ee8edd8c40abb93cd0
    127 schema:sameAs https://app.dimensions.ai/details/publication/pub.1107776066
    128 https://doi.org/10.1186/s40425-018-0420-0
    129 schema:sdDatePublished 2022-09-02T16:02
    130 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    131 schema:sdPublisher N02ec90db46e04462bb0e133ccde314a7
    132 schema:url https://doi.org/10.1186/s40425-018-0420-0
    133 sgo:license sg:explorer/license/
    134 sgo:sdDataset articles
    135 rdf:type schema:ScholarlyArticle
    136 N02ec90db46e04462bb0e133ccde314a7 schema:name Springer Nature - SN SciGraph project
    137 rdf:type schema:Organization
    138 N09679885948b4bd79d7b65370b9ba11e rdf:first sg:person.0616232204.47
    139 rdf:rest N4c00e825bcbd468cbea295a42e51f7bf
    140 N0d8db430ff674225846c57851db350c3 rdf:first sg:person.01255266321.73
    141 rdf:rest N281f6d1e0df74a02b48a42eb94301a83
    142 N1efb180265214dfa89c8b4393ef7fbe4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    143 schema:name Middle Aged
    144 rdf:type schema:DefinedTerm
    145 N2712b57e3c1e4a1181251c25c7356557 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    146 schema:name Kidney Neoplasms
    147 rdf:type schema:DefinedTerm
    148 N281f6d1e0df74a02b48a42eb94301a83 rdf:first sg:person.016162310137.44
    149 rdf:rest Nc27b0826f0384b6a8dae5acdbc9a67c2
    150 N28d12ca478eb4cd884451905382bd1ee rdf:first sg:person.0577111044.36
    151 rdf:rest N319efe8217424fd48a1258a5d89caa6d
    152 N292e5407421b494192f82997c12bff04 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    153 schema:name Female
    154 rdf:type schema:DefinedTerm
    155 N29faa800a443484e83f55169e5d071d4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    156 schema:name Aged
    157 rdf:type schema:DefinedTerm
    158 N319efe8217424fd48a1258a5d89caa6d rdf:first sg:person.01275717732.80
    159 rdf:rest N0d8db430ff674225846c57851db350c3
    160 N31ca3ef3c6ff488fba0c2db9113c292d rdf:first sg:person.01115160302.45
    161 rdf:rest Nbb57af391fa147d89d3709b34735e55b
    162 N3bbe0469ea444b2fb42b7d52df88b09a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    163 schema:name Male
    164 rdf:type schema:DefinedTerm
    165 N41e7fe3450854a499af185bbff107c95 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    166 schema:name Humans
    167 rdf:type schema:DefinedTerm
    168 N46c8710e115a4ea0b719e39f1b2968f8 schema:name pubmed_id
    169 schema:value 30348216
    170 rdf:type schema:PropertyValue
    171 N4c00e825bcbd468cbea295a42e51f7bf rdf:first sg:person.0726044621.91
    172 rdf:rest N31ca3ef3c6ff488fba0c2db9113c292d
    173 N75070f88dd514ddba8f724ab961bab20 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    174 schema:name Carcinoma, Renal Cell
    175 rdf:type schema:DefinedTerm
    176 N7fe02277ec5d40df97bb03e754da565a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    177 schema:name Indazoles
    178 rdf:type schema:DefinedTerm
    179 N870de9f794564cfebfdcc70a49a9f1cc rdf:first sg:person.01270061622.88
    180 rdf:rest N28d12ca478eb4cd884451905382bd1ee
    181 N979187772f4a4f2bac77ab78310fc222 schema:issueNumber 1
    182 rdf:type schema:PublicationIssue
    183 N979458981edb4e52bd347018f48dd9ee schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    184 schema:name Antineoplastic Combined Chemotherapy Protocols
    185 rdf:type schema:DefinedTerm
    186 N992be4c452224b079854537071f3825c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    187 schema:name Adult
    188 rdf:type schema:DefinedTerm
    189 N99c078a5cae94490b2607e3f74663204 rdf:first sg:person.01343430002.75
    190 rdf:rest Nc06162a28b014c18acb1b93ec8f41912
    191 N99ce20905a804798b6341f3d65abdb1f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    192 schema:name Pyrimidines
    193 rdf:type schema:DefinedTerm
    194 Na092b92f231d48f0908612839645f340 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    195 schema:name Sulfonamides
    196 rdf:type schema:DefinedTerm
    197 Nae0046fc25e54bcfbc97451bc74995a7 schema:name doi
    198 schema:value 10.1186/s40425-018-0420-0
    199 rdf:type schema:PropertyValue
    200 Nb1d751ef7bf945f1ace30db13a26f6f0 rdf:first sg:person.010437732204.73
    201 rdf:rest N870de9f794564cfebfdcc70a49a9f1cc
    202 Nb4e8af68b6db4d189f943442cfc6c5b7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    203 schema:name Nivolumab
    204 rdf:type schema:DefinedTerm
    205 Nb599fc2409a74192a76845847d67a453 rdf:first sg:person.01113325143.17
    206 rdf:rest Nb1d751ef7bf945f1ace30db13a26f6f0
    207 Nbb57af391fa147d89d3709b34735e55b rdf:first sg:person.014017277612.37
    208 rdf:rest N99c078a5cae94490b2607e3f74663204
    209 Nc06162a28b014c18acb1b93ec8f41912 rdf:first sg:person.0656541200.82
    210 rdf:rest Necc557c73c6a4a4b837b0d75efe16e67
    211 Nc27b0826f0384b6a8dae5acdbc9a67c2 rdf:first sg:person.01220204543.52
    212 rdf:rest rdf:nil
    213 Ne7a7dd34fcd24991806fd7d71b599720 schema:volumeNumber 6
    214 rdf:type schema:PublicationVolume
    215 Necc557c73c6a4a4b837b0d75efe16e67 rdf:first sg:person.01266317743.88
    216 rdf:rest Nfdb3178285b44ae295d33145da8dcff0
    217 Nee59aff7666447ee8edd8c40abb93cd0 schema:name dimensions_id
    218 schema:value pub.1107776066
    219 rdf:type schema:PropertyValue
    220 Nfdb3178285b44ae295d33145da8dcff0 rdf:first sg:person.0660645031.33
    221 rdf:rest Nb599fc2409a74192a76845847d67a453
    222 Nfee72279967248199482ed3e0aa6a65d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    223 schema:name Sunitinib
    224 rdf:type schema:DefinedTerm
    225 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    226 schema:name Medical and Health Sciences
    227 rdf:type schema:DefinedTerm
    228 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
    229 schema:name Clinical Sciences
    230 rdf:type schema:DefinedTerm
    231 sg:grant.2438793 http://pending.schema.org/fundedItem sg:pub.10.1186/s40425-018-0420-0
    232 rdf:type schema:MonetaryGrant
    233 sg:journal.1049249 schema:issn 2051-1426
    234 schema:name Journal for ImmunoTherapy of Cancer
    235 schema:publisher BMJ
    236 rdf:type schema:Periodical
    237 sg:person.010437732204.73 schema:affiliation grid-institutes:grid.22072.35
    238 schema:familyName Heng
    239 schema:givenName Daniel Y C
    240 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010437732204.73
    241 rdf:type schema:Person
    242 sg:person.01113325143.17 schema:affiliation grid-institutes:grid.254293.b
    243 schema:familyName Rini
    244 schema:givenName Brian I
    245 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01113325143.17
    246 rdf:type schema:Person
    247 sg:person.01115160302.45 schema:affiliation grid-institutes:grid.240614.5
    248 schema:familyName Ernstoff
    249 schema:givenName Marc S
    250 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01115160302.45
    251 rdf:type schema:Person
    252 sg:person.01220204543.52 schema:affiliation grid-institutes:None
    253 schema:familyName Hammers
    254 schema:givenName Hans J
    255 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01220204543.52
    256 rdf:type schema:Person
    257 sg:person.01255266321.73 schema:affiliation grid-institutes:grid.419971.3
    258 schema:familyName Berghorn
    259 schema:givenName Elmer
    260 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01255266321.73
    261 rdf:type schema:Person
    262 sg:person.01266317743.88 schema:affiliation grid-institutes:grid.280502.d
    263 schema:familyName Carducci
    264 schema:givenName Michael
    265 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01266317743.88
    266 rdf:type schema:Person
    267 sg:person.01270061622.88 schema:affiliation grid-institutes:grid.415224.4
    268 schema:familyName Knox
    269 schema:givenName Jennifer
    270 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01270061622.88
    271 rdf:type schema:Person
    272 sg:person.01275717732.80 schema:affiliation grid-institutes:grid.17089.37
    273 schema:familyName Spratlin
    274 schema:givenName Jennifer
    275 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01275717732.80
    276 rdf:type schema:Person
    277 sg:person.01343430002.75 schema:affiliation grid-institutes:grid.419513.b
    278 schema:familyName Bauer
    279 schema:givenName Todd M
    280 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01343430002.75
    281 rdf:type schema:Person
    282 sg:person.014017277612.37 schema:affiliation grid-institutes:grid.413480.a
    283 schema:familyName Lewis
    284 schema:givenName Lionel D
    285 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014017277612.37
    286 rdf:type schema:Person
    287 sg:person.016162310137.44 schema:affiliation grid-institutes:grid.419971.3
    288 schema:familyName Yang
    289 schema:givenName Lingfeng
    290 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016162310137.44
    291 rdf:type schema:Person
    292 sg:person.0577111044.36 schema:affiliation grid-institutes:grid.51462.34
    293 schema:familyName Voss
    294 schema:givenName Martin H
    295 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0577111044.36
    296 rdf:type schema:Person
    297 sg:person.0616232204.47 schema:affiliation grid-institutes:grid.468189.a
    298 schema:familyName Amin
    299 schema:givenName Asim
    300 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0616232204.47
    301 rdf:type schema:Person
    302 sg:person.0656541200.82 schema:affiliation grid-institutes:grid.239395.7
    303 schema:familyName McDermott
    304 schema:givenName David F
    305 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0656541200.82
    306 rdf:type schema:Person
    307 sg:person.0660645031.33 schema:affiliation grid-institutes:grid.248762.d
    308 schema:familyName Kollmannsberger
    309 schema:givenName Christian
    310 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0660645031.33
    311 rdf:type schema:Person
    312 sg:person.0726044621.91 schema:affiliation grid-institutes:grid.249335.a
    313 schema:familyName Plimack
    314 schema:givenName Elizabeth R
    315 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726044621.91
    316 rdf:type schema:Person
    317 sg:pub.10.1038/bjc.2015.196 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003895805
    318 https://doi.org/10.1038/bjc.2015.196
    319 rdf:type schema:CreativeWork
    320 sg:pub.10.1186/s40425-017-0310-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1100433878
    321 https://doi.org/10.1186/s40425-017-0310-x
    322 rdf:type schema:CreativeWork
    323 grid-institutes:None schema:alternateName Department of Internal Medicine, UT Southwestern – Kidney Cancer Program, 75390, Dallas, TX, USA
    324 schema:name Department of Internal Medicine, UT Southwestern – Kidney Cancer Program, 75390, Dallas, TX, USA
    325 rdf:type schema:Organization
    326 grid-institutes:grid.17089.37 schema:alternateName Department of Oncology, Cross Cancer Institute, University of Alberta, T6G 1Z2, Edmonton, AB, Canada
    327 schema:name Department of Oncology, Cross Cancer Institute, University of Alberta, T6G 1Z2, Edmonton, AB, Canada
    328 rdf:type schema:Organization
    329 grid-institutes:grid.22072.35 schema:alternateName Department of Oncology, Tom Baker Cancer Center, University of Calgary, T2N 4N2, Calgary, AB, Canada
    330 schema:name Department of Oncology, Tom Baker Cancer Center, University of Calgary, T2N 4N2, Calgary, AB, Canada
    331 rdf:type schema:Organization
    332 grid-institutes:grid.239395.7 schema:alternateName Department of Medicine, Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, 02215, Boston, MA, USA
    333 schema:name Department of Medicine, Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, 02215, Boston, MA, USA
    334 rdf:type schema:Organization
    335 grid-institutes:grid.240614.5 schema:alternateName Division of Oncology, Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, 14203, Buffalo, NY, USA
    336 schema:name Division of Oncology, Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, 14203, Buffalo, NY, USA
    337 rdf:type schema:Organization
    338 grid-institutes:grid.248762.d schema:alternateName Division of Medical Oncology, British Columbia Cancer Agency, V5Z 4E6, Vancouver, BC, Canada
    339 schema:name Division of Medical Oncology, British Columbia Cancer Agency, V5Z 4E6, Vancouver, BC, Canada
    340 rdf:type schema:Organization
    341 grid-institutes:grid.249335.a schema:alternateName Division of Genitourinary Medical Oncology, Department of Hematology/Oncology, Fox Chase Cancer Center, 19111, Philadelphia, PA, USA
    342 schema:name Division of Genitourinary Medical Oncology, Department of Hematology/Oncology, Fox Chase Cancer Center, 19111, Philadelphia, PA, USA
    343 rdf:type schema:Organization
    344 grid-institutes:grid.254293.b schema:alternateName Lerner College of Medicine, Department of Hematology and Oncology, Cleveland Clinic Taussig Cancer Institute, 44195, Cleveland, OH, USA
    345 schema:name Lerner College of Medicine, Department of Hematology and Oncology, Cleveland Clinic Taussig Cancer Institute, 44195, Cleveland, OH, USA
    346 rdf:type schema:Organization
    347 grid-institutes:grid.280502.d schema:alternateName Department of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, 21287, Baltimore, MD, USA
    348 schema:name Department of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, 21287, Baltimore, MD, USA
    349 rdf:type schema:Organization
    350 grid-institutes:grid.413480.a schema:alternateName Department of Medicine at The Geisel School of Medicine and The Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, 03756, Lebanon, NH, USA
    351 schema:name Department of Medicine at The Geisel School of Medicine and The Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, 03756, Lebanon, NH, USA
    352 rdf:type schema:Organization
    353 grid-institutes:grid.415224.4 schema:alternateName Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre, M5G 1Z5, Toronto, ON, Canada
    354 schema:name Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre, M5G 1Z5, Toronto, ON, Canada
    355 rdf:type schema:Organization
    356 grid-institutes:grid.419513.b schema:alternateName Sarah Cannon Research Institute/Tennessee Oncology, PLLC, 37203, Nashville, TN, USA
    357 schema:name Sarah Cannon Research Institute/Tennessee Oncology, PLLC, 37203, Nashville, TN, USA
    358 rdf:type schema:Organization
    359 grid-institutes:grid.419971.3 schema:alternateName Oncology - Global Clinical Research, Bristol-Myers Squibb, 08541, Princeton, NJ, USA
    360 schema:name Oncology - Global Clinical Research, Bristol-Myers Squibb, 08541, Princeton, NJ, USA
    361 rdf:type schema:Organization
    362 grid-institutes:grid.468189.a schema:alternateName Immunotherapy program, Levine Cancer Institute, Carolinas HealthCare System, 1024 Morehead Medical Drive, 28204, Charlotte, NC, USA
    363 schema:name Immunotherapy program, Levine Cancer Institute, Carolinas HealthCare System, 1024 Morehead Medical Drive, 28204, Charlotte, NC, USA
    364 rdf:type schema:Organization
    365 grid-institutes:grid.51462.34 schema:alternateName Department of Medicine, Memorial Sloan Kettering Cancer Center, 10065, New York, NY, USA
    366 schema:name Department of Medicine, Memorial Sloan Kettering Cancer Center, 10065, New York, NY, USA
    367 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...